Exclusive: J&J discussing breaking up Actelion in an acquisition - sources

(Reuters) - Johnson & Johnson is negotiating a deal to acquire Swiss biotechnology company Actelion Ltd that would separate its commercialized portfolio from its research and development (R&D) assets, people familiar with the matter said on Thursday.

Exclusive: J&J discussing breaking up Actelion in an acquisition - sources
Read More


Bagikan Berita Ini